|
| |
| Some dyamides are under preclinical development as intravascular MRI contrast agents for blood flow perfusion.
Short name: Dy-DTPA-BMA, generic name: Sprodyamide, central moiety: Dy2+, contrast effect: T2*enhanced, relaxivity: r1=3.4, r2=3.8, B0=0.47,
Short name: Dy-DTPA, central moiety: Dy2+, contrast effect: T2*enhanced,
Short name: Albumin-(Dy-DTPA)x, central moiety: Dy2+, contrast effect: T2*enhanced.
| |
|
| | Further Reading: | Basics:
|
|
| |